Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-25032026-271286
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1517]
NEW DELHI, WEDNESDAY, MARCH 25, 2026/CHAITRA 4, 1948
2199 GI/2026
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 25th March, 2026
S.O. 1582(E)— In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs
(Prices Control) Order, 2013, read with S.O. No. 1394(E) dated 30th May, 2013, S.O. 5249(E) dated 11th November,
2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s)
of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority)
S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical
Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive
of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding
entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the
corresponding entries in columns (3) and (4) thereof:
TABLE
Price Revision as per Annual Wholesale Price Index (WPI) @ 0.64956% increase
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| Sl. | Medicines | Dosage form and | Unit | Ceiling price | Existing S.O., No. & Date |
| No. | | strength | | (w.e.f. 1.4.2026 | | |
| | | | | with WPI @ | | |
| | | | | 0.64956%) | | |
| | | | | (in Rs.) | | |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| (1) | (2) | (3) | (4) | (5) | (6a) | (6b) |
+=====+===================================+=====================+============+===========================+============+============+
| 1 | Acetyl Salicylic Acid | Tablet 300mg | 1 Tablet | 0.28 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| 2 | Calcium carbonate | Tablet 250 mg | 1 Tablet | 2.49 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| 3 | Condoms | | 1 Condom | 11.65 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| 4 | Dapsone | Tablet 50 mg | 1 Tablet | 0.30 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| 5 | Medroxy Progesterone Acetate | Tablet 5mg | 1 Tablet | 3.80 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
| 6 | Rifampicin | Tablet 450mg | 1 Tablet | 5.66 | 1488(E) | 27-03-2025 |
+-----+-----------------------------------+---------------------+------------+---------------------------+------------+------------+
Notes:
(a) The ceiling prices are applicable with effect from 1.4.2026 (ceiling prices are inclusive of Wholesale Price
Index (WPI) @ 0.64956% for the year 2025 over 2024).
(b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling
price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.
(c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling
price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and
Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI
@0.64956% for year 2025 over 2024 in accordance with paragraph 16(2) of DPCO, 2013.
(d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail
price (MRP), along with interest thereon from the date of overcharging.
(f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form-I as specified under Schedule-II of the
DPCO, 2013.
(i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect
of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the DPCO, 2013 read with
Essential Commodities Act, 1955.
(k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/276/144/2026/F/F. No. 8(144)/2026/D.P./NPPA-Div.-II]
BHIVA RAM YADAV, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
Login to read full text